IRVINE, Calif., Aug. 8 /EMWNews/ -- ChromaDex Corporation

(OTC Bulletin Board: CDXC), a leader in the development of phytochemical

and botanical reference standards, today announced that on July 29, 2008,

it completed its last round of sales under a private placement it conducted

with its wholly owned subsidiary ChromaDex, Inc., which consisted of the

sale of a unit of one share of common stock and a warrant to purchase one

half the shares of common stock purchased for a price of $1.36 per unit.

The private placement, which was authorized for up to $6 million and has

been on-going since March, yielded gross proceeds of approximately $4.67

million. Net proceeds after expenses are expected to be approximately $4.2

million. New Castle Financial Services acted as placement agent for the

private placement.



    Frank Jaksch, co-founder and Chief Executive Officer of ChromaDex,

commented, "Subsequent to our recent emergence as a publicly-traded company

through completion of a reverse merger, today we are pleased to announce

the closing of this private placement to provide ChromaDex with additional

working capital to support our business expansion plans. We are pleased

with the amount raised and confident this financing will help position

ChromaDex to support the next phase of growth in our quest to become the

premier provider of phytochemical and botanical reference standards to the

functional food, cosmetic, dietary supplement, pharmaceutical / life

sciences and other industries."



    ChromaDex expects to use the net proceeds to fund organic expansion as

well as for general corporate purposes and working capital. Neither the

sale nor issuance of the shares of common stock, warrants or the shares of

common stock underlying the warrants in this transaction have been

registered under the Securities Act of 1933, as amended, or applicable

state securities laws and will not be offered, sold or transferred absent

registration or an exemption from registration.

    About ChromaDex



    ChromaDex is a leader in the development of Phytochemical and Botanical

Reference Standards and the creation of associated intellectual property.

ChromaDex is committed to sustainable, "Green chemistry" and provides the

dietary supplement, food, beverage, nutraceutical and cosmetic industries

with the analytical tools, products, and services to meet the regulatory,

quality, efficacy and safety standards for their products.



    Forward-Looking Statements



    Any statements that are not historical facts contained in this release

are forward-looking statements. Actual results may differ materially from

those projected or implied in any forward-looking statements. Such

statements involve risks and uncertainties, including but not limited to

those relating to product and customer demand, market acceptance of our

products, the effect of economic conditions both nationally and

internationally, ability to protect our intellectual property rights,

impact of any litigation or infringement actions brought against us,

competition from other providers and products, risks in product

development, our ability to raise capital to fund continuing operations,

the ability to complete transactions, and other factors discussed from time

to time in the Company's Securities and Exchange Commission filings. The

Company undertakes no obligation to update or revise any forward-looking

statement for events or circumstances after the date on which such

statement is made except as required by law.